Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Thiogenesis Therapeutics Corp V.TTI

Alternate Symbol(s):  TTIPF

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).


TSXV:TTI - Post by User

Thiogenesis Therapeutics Corp > listing today
<< Previous
 Bullboard Posts
User Avatar Image
(12)
•••
Comment by Bassenon123on Apr 22, 2022 3:36am
87 Views
Post# 34622846

RE:RE:RE:RE:listing today

RE:RE:RE:RE:listing today H1..
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities